$IVVD News

Last published 1w ago

1w agoIVVDInvivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW HAVEN, Conn., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that on November 1, 2026, Invivyd granted seven newly hired non-executive employees options to purchase an aggregate of
3w agoIVVDInvivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026GlobeNewswireVMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd VMS063 demonstrated potent in vitro antiviral activity against contemporary measles virus
4w agoIVVDInvivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination SyndromeGlobeNewswireFLINTLOCK Phase 2 clinical trial will evaluate the safety, tolerability, pharmacokinetics, and clinical efficacy of high-dose monoclonal antibody VYD2311 in adults aged 18-65 years with Long COVID or Post-Vaccination
1mo agoIVVDInvivyd Conference Call - INVIVYD INCEarnings Call TranscriptsGood day, and thank you for standing by. Welcome to the InVivid Topline Liberty Data and VYD 2311 Next Steps, September 29, 2026. At this time, all participants are in a listen-only mode. After the speaker's presentation
2mo agoIVVDInvivyd to Participate in Upcoming September Investor ConferencesGlobeNewswireNEW HAVEN, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that Marc W. Elia, Chairman and Chief Executive Officer, and members of company management will participate in three
2mo agoIVVDInvivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that on September 1, 2026, Invivyd granted six newly hired non-executive employees options to purchase an aggregate of
2mo agoIVVDInvivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTYGlobeNewswireMr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected Invivyd’s scientific and corporate strategyAjay Royan, Founder of Mithril Capital and a founding, long-term investor in
3mo agoIVVDInvivyd Reports Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswireAchieved Q2 2026 PEMGARDA® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 millionCompleted rapid enrollment in VYD2311 DECLARATION clinical trial
3mo agoIVVDInvivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW HAVEN, Conn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that on August 1, 2026, Invivyd granted ten newly hired non-executive employees options to purchase an aggregate of
4mo agoIVVDInvivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDAGlobeNewswireU.S. Department of Health and Human Services (HHS) announced advanced Notice of Termination of the COVID-19 EUA declaration, effective June 29, 2027 Consequently, Invivyd received from the U.S. Food and Drug
4mo agoIVVDInvivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW HAVEN, Conn., July 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that on July 1, 2026, Invivyd granted 14 newly hired non-executive employees options to purchase an aggregate of 493,000
4mo agoNBP IVVDNovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive OfficerGlobeNewswireROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) ("NovaBridge" or the "Company"), a clinical-stage biopharmaceutical company advancing innovative medicines for
4mo agoIVVDInvivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 VaccineGlobeNewswireInvivyd expects to report topline data from LIBERTY in Q3 2026Data from LIBERTY can provide important insight into the VYD2311 clinical profile by direct comparison between COVID antibody prophylaxis and COVID vaccine
5mo agoIVVDInvivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-AdministrationGlobeNewswireLIBERTY clinical trial will evaluate the comparative safety and tolerability of VYD2311 versus mRNA COVID-19 vaccine, as well as explore the safety and immunology of co-administered VYD2311 and mRNA COVID-19
5mo agoIVVDInvivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW HAVEN, Conn., June 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that on June 1, 2026, Invivyd granted 17 newly hired non-executive employees options to purchase an aggregate of 513,500
5mo agoIVVDInvivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVIDGlobeNewswireDECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of symptomatic COVID-19 versus placebo, at three months, from a single
5mo agoIVVDInvivyd to Participate in Upcoming Investor EventsGlobeNewswireNEW HAVEN, Conn., May 27, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that it will participate in upcoming investor events in June: 2026 Jefferies Global Healthcare Conference in New
6mo agoIVVDQ1 2026 Invivyd Earnings Conference CallINVIVYD INCEarnings Call TranscriptsGood day, and thank you for standing by. Welcome to the NVIDIA First Quarter 2026 Earnings Conference Call. At this time, all participants are in the listen-only mode. After the speaker's presentation, there will be a qu
6mo agoIVVDInvivyd Reports First Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswireAchieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 millionInvivyd in vitro data showed continued neutralizing activity
6mo agoIVVDInvivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID VaccinationGlobeNewswireInvivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody adintrevimab from the EVADE study, demonstrating minimal tolerability issuesResults allow for comparison to contemporary
6mo agoIVVDInvivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026GlobeNewswireNEW HAVEN, Conn., May 07, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a
6mo agoIVVDInvivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that on May 1, 2026, Invivyd granted 17 newly hired non-executive employees options to purchase an aggregate of 731,000
6mo agoIVVDInvivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care SummitGlobeNewswireElia to speak at the premier gathering of policy makers, industry leaders, and health experts between 11:30 AM ET – 12:00 PM ET on April 21Event to be live streamed between 9:00 AM – 1:00 PM ET NEW HAVEN, Conn., April
7mo agoIVVDInvivyd Revolution Program & Measles Update Conference CallINVIVYD INCEarnings Call TranscriptsGood day, and welcome to the InVivid Revolution Program and Measles Update Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer se
7mo agoIVVDInvivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of MeaslesGlobeNewswireConfirmed, pooled, blinded COVID-19 events in the ongoing Phase 3 DECLARATION study of VYD2311 accumulated to date (~ 50% of study progress) can already provide sufficient statistical power to support the high end of
7mo agoIVVDInvivyd Launches "Antibodies for Any Body" in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune HealthGlobeNewswireNational education campaign aims to educate Americans about antibodies and their role in immune healthCampaign centerpiece, AntibodiesforAnyBody.com, offers an interactive immune health wellness assessment to empower
7mo agoIVVDInvivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW HAVEN, Conn., April 06, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that on April 1, 2026, Invivyd granted 16 newly hired non-executive employees options to purchase an aggregate of
7mo agoIVVDInvivyd Announces Presentation at the World Vaccine Congress WashingtonGlobeNewswireChief Scientific Officer, Robert Allen, Ph.D., presented as part of the "Antibodies for Infectious Disease Workshop" at the World Vaccine Congress WashingtonPresentation titled "Developing mAb Therapies that Keep Pace
8mo agoIVVDInvivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial UpdatesGlobeNewswireAchieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of $226.7 million after
8mo agoIVVDInvivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical OfficerGlobeNewswireFormer assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital, Dr. Mina
8mo agoIVVDInvivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026GlobeNewswireNEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a
8mo agoIVVDInvivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that on March 1, 2026, Invivyd granted four newly hired non-executive employees options to purchase an aggregate of
8mo agoIVVDNew Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 AntibodiesGlobeNewswire"A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19" was published in Infectious
9mo agoIVVDInvivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-AdministrationGlobeNewswireLIBERTY is part of the Company's broader REVOLUTION clinical program designed to elaborate the profile of monoclonal antibody-mediated prophylaxis from COVID-19 and the potential medical benefits to vulnerable
9mo agoIVVDInvivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease PreventionGlobeNewswireThe educational campaign will focus on teaching the American public about antibodies and preventing infectious diseaseThe collaboration will advance public understanding of antibodies as a centerpiece of modern wellness
9mo agoIVVDInvivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026GlobeNewswirePhase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injuryParticipants to include people with Long COVID who
10mo agoIVVDInvivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business HighlightsGlobeNewswirePreliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarterPreliminary ending 2025 cash and cash equivalents of $226.7
10mo agoIVVDInvivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVIDGlobeNewswireNEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an investigational
10mo agoIVVDInvivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVIDGlobeNewswireDECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID versus placebo, at three months, from a single intramuscular (IM) dose,
11mo agoIVVDInvivyd to Participate at the 8th Annual Evercore Healthcare ConferenceGlobeNewswireNEW HAVEN, Conn., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December
11mo agoIVVDInvivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND ReadinessGlobeNewswireVBY329 is designed for the prevention of Respiratory Syncytial Virus (RSV) infections in newborns, infants, and children, and results from Invivyd's proprietary antibody discovery technology platformVBY329 meets
11mo agoIVVDInvivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireNEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (NASDAQ:IVVD) today announced the pricing of an underwritten public offering of 44,000,000 shares of its common stock at an offering price of
11mo agoIVVDInvivyd Announces Proposed Public Offering of Common StockGlobeNewswireNEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (NASDAQ:IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd
1y agoIVVDInvivyd Reports Third Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswirePEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth quarter-over-quarterOctober 2025 ending cash and cash equivalents of over $100
1y agoIVVDInvivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025GlobeNewswireNEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a
1y agoIVVDInvivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVIDGlobeNewswireNEW HAVEN, Conn., Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: Invivyd, Inc. (NASDAQ:IVVD) is hosting the previously announced live webcast to present an overview of the company's REVOLUTION clinical program, Invivyd's
1y agoIVVDInvivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVIDGlobeNewswireThe DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID vaccination) clinical trials are expected to begin around year-end 2025; top-line data
1y agoIVVDInvivyd Appoints Paul B. Bolno, M.D. to Its Board of DirectorsGlobeNewswireNEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr.
1y agoIVVDInvivyd Announces Appointment of Kristie Kuhl as Chief Communications OfficerGlobeNewswireNEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced the appointment of Kristie Kuhl as Chief Communications Officer. Ms. Kuhl will lead the Company's communications and
1y agoIVVDSPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025GlobeNewswireSPEAR proposal reflects current evidence on monoclonal antibodies in treatment for Long COVID and identifies VYD2311 as a promising next-generation candidate for the clinical study Recommendation is for a robust,